Εμφανίζονται 1 - 20 Αποτελέσματα από 123 για την αναζήτηση '"СТЕНТИРОВАНИЕ КОРОНАРНЫХ АРТЕРИЙ"', χρόνος αναζήτησης: 0,93δλ Περιορισμός αποτελεσμάτων
  1. 1
  2. 2
    Academic Journal

    Συνεισφορές: Авторы заявляют об отсутствии финансирования исследования.

    Πηγή: Complex Issues of Cardiovascular Diseases; Том 14, № 5 (2025); 27-35 ; Комплексные проблемы сердечно-сосудистых заболеваний; Том 14, № 5 (2025); 27-35 ; 2587-9537 ; 2306-1278

    Περιγραφή αρχείου: application/pdf

    Relation: https://www.nii-kpssz.com/jour/article/view/1601/1084; https://www.nii-kpssz.com/jour/article/downloadSuppFile/1601/1908; Moreno-Angarita, A., Peña, D., de León, J.D.LP. et al. Current indications and surgical strategies for myocardial revascularization in patients with left ventricular dysfunction: a scoping review. J Cardiothorac Surg 19, 469 (2024). https://doi.org/10.1186/s13019-024-02844-2; Алекян Б.Г., Бойцов С.А., Маношкина Е.М., Ганюков В.И. Реваскуляризация миокарда в Российской Федерации при остром коронарном синдроме в 2016-2020 гг. Кардиология. 2021;61(12):4-15. https://doi.org/10.18087/cardio.2021.12.n1879; Иванов С.В., Сумин А.Н. Современные тенденции рутинной реваскуляризации миокарда. Комплексные проблемы сердечно-сосудистых заболеваний. 2021;10(2):25-35. https://doi.org/10.17802/2306-1278-2021-10-2-25-35; Llerena-Velastegui J, Zumbana-Podaneva K, Velastegui-Zurita S, Mejia-Mora M, Perez-Tomassetti J, Cabrera-Cruz A, Haro-Arteaga P, de Jesus ACFS, Coelho PM, Sanahuja-Montiel C. Comparative Efficacy of Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in the Treatment of Ischemic Heart Disease: A Systematic Review and Meta-Analysis of Recent Randomized Controlled Trials. Cardiol Res. 2024 Jun;15(3):153-168. doi:10.14740/cr1638.; Барбараш О.Л., Карпов Ю.А., Панов А.В., и др. Стабильная ишемическая болезнь сердца. Клинические рекомендации 2024. Российский кардиологический журнал. 2024;29(9):6110. doi:10.15829/1560-4071-2024-6110.; Российское кардиологическое общество (РКО) . Острый инфаркт миокарда с подъемом сегмента ST электрокардиограммы. Клинические рекомендации; Cui K, Liu H, Yuan F, et al. Coronary artery bypass graft surgery versus stenting for patients with chronic kidney disease and complex coronary artery disease: a systematic review and meta-analysis. Therapeutic Advances in Chronic Disease. 2021;12. doi:10.1177/2040622321990273; Caldonazo, T., Kirov, H., Riedel, L.L. et al. Comparing CABG and PCI across the globe based on current regional registry evidence. Sci Rep 12, 22164 (2022). https://doi.org/10.1038/s41598-022-25853-4; Самородская И.В. , Какорина Е.П. Динамика хирургического и эндоваскулярного лечения ишемической болезни сердца в Российской Федерации (2014-2023гг). Часть 1. Комплексные проблемы сердечно-сосудистых заболеваний. 2025 (принята к печати); Барбараш О.Л., Кашталап В.В., Шибанова И.А., Коков А.Н. Фундаментальные и прикладные аспекты кальцификации коронарных артерий. Российский кардиологический журнал. 2020;25(3S):4005. https://doi.org/10.15829/1560-4071-2020-4005; Nogueira-Garcia B, Vilela M, Oliveira C, Caldeira D, Martins AM, Nobre Menezes M. A Narrative Review of Revascularization in Chronic Coronary Syndrome/Disease: Concepts and Misconceptions. J Pers Med. 2024 May 10;14(5):506. doi:10.3390/jpm14050506.; Patel KK, Peri-Okonny PA, Giorgetti A, Shaw LJ, Gimelli A. Value of Ischemia and Coronary Anatomy in Prognosis and Guiding Revascularization Among Patients With Stable Ischemic Heart Disease. Circ Cardiovasc Imaging. 2024 Sep;17(9):e016587. doi:10.1161/CIRCIMAGING.123.016587.; Bangalore S, Rhodes G, Maron DJ, Anthopolos R, O'Brien SM, Jones PG, Mark DB, Reynolds HR, Spertus JA, Stone GW, White HD, Xu Y, Fremes SE, Hochman JS, Ischemia Research Group OBOT. Outcomes with revascularisation versus conservative management of participants with 3-vessel coronary artery disease in the ISCHEMIA trial. EuroIntervention. 2024 Oct 21;20(20):e1276-e1287. doi:10.4244/EIJ-D-24-00240.; Timmis A, Aboyans V, Vardas P, Townsend N, Torbica A, Kavousi M, Boriani G, Huculeci R, Kazakiewicz D, Scherr D, Karagiannidis E, Cvijic M, Kapłon-Cieślicka A, Ignatiuk B, Raatikainen P, De Smedt D, Wood A, Dudek D, Van Belle E, Weidinger F; ESC National Cardiac Societies. European Society of Cardiology: the 2023 Atlas of Cardiovascular Disease Statistics. Eur Heart J. 2024 Oct 7;45(38):4019-4062. doi:10.1093/eurheartj/ehae466.; Kumsa NB, Kelly TL, Roughead EE, Tavella R, Gillam MH. Temporal trends in percutaneous coronary intervention in Australia: A retrospective analysis from 2000-2021. Hellenic J Cardiol. 2024 Nov-Dec;80:21-30. doi:10.1016/j.hjc.2023.10.002; Tam DY, Qiu F, Manoragavan R, Fremes SE, Hassan A, Ko DT, Lauck SB, Naimark D, Ouzounian M, Sander B, Sun L, Wijeysundera HC. The Impact of the COVID-19 Pandemic on Cardiac Procedure Wait List Mortality in Ontario, Canada. Can J Cardiol. 2021 Oct;37(10):1547-1554. doi:10.1016/j.cjca.2021.05.008.; Aranda-Michel E, Serna-Gallegos D, Arnaoutakis G, Kilic A, Brown JA, Dai Y, Dunn-Lewis C, Sultan I. The Effect of COVID-19 on Cardiac Surgical Volume and its Associated Costs. Semin Thorac Cardiovasc Surg. 2023 Autumn;35(3):508-515. doi:10.1053/j.semtcvs.2022.01.009.; Ivert T, Dalén M, Friberg Ö. Effect of COVID-19 on cardiac surgery volumes in Sweden. Scand Cardiovasc J. 2023 Dec;57(1):2166102. doi:10.1080/14017431.2023.2166102.; Goicolea Ruigómez FJ, Elola FJ, Durante-López A, Fernández Pérez C, Bernal JL, Macaya C. Coronary artery bypass grafting in Spain. Influence of procedural volume on outcomes. Rev Esp Cardiol (Engl Ed). 2020 Jun;73(6):488-494. English, Spanish. doi:10.1016/j.rec.2019.08.016; Jones DA, Gallagher S, Rathod K, Jain AK, Mathur A, Uppal R, Westwood M, Wong K, Rothman MT, Shipolini A, Smith EJ, Mills PG, Timmis AD, Knight CJ, Archbold RA, Wragg A. Clinical outcomes after myocardial revascularization according to operator training status: cohort study of 22,697 patients undergoing percutaneous coronary intervention or coronary artery bypass graft surgery. Eur Heart J. 2013 Oct;34(37):2887-95. doi:10.1093/eurheartj/eht161.; Эфрос Л.А., Лукин О.П., Самородская И.В., Семенов В.Ю., Сумин А.Н., Иванов С.В., Евсеева М.В., Барбараш О.Л. Коморбидная патология у больных ишемической болезнью сердца при коронарном шунтировании среди пациентов кардиохирургических центров Челябинска и Кемерово. Комплексные проблемы сердечно-сосудистых заболеваний. 2017;6(4):71-79. https://doi.org/10.17802/2306-1278-2017-6-4-71-79 (In Russ.); Барбараш О.Л., Семенов В.Ю., Самородская И.В., Евсеева М.В., Рожков Н.А., Сумин А.Н., Барбараш Л.С. Коморбидная патология у больных ишемической болезнью сердца при коронарном шунтировании: опыт двух кардиохирургических центров. Российский кардиологический журнал. 2017;(3):6-13. https://doi.org/10.15829/1560-4071-2017-3-6-13

  3. 3
    Academic Journal

    Συνεισφορές: Авторы заявляют об отсутствии финансирования исследования.

    Πηγή: Complex Issues of Cardiovascular Diseases; Том 14, № 4 (2025); 68-76 ; Комплексные проблемы сердечно-сосудистых заболеваний; Том 14, № 4 (2025); 68-76 ; 2587-9537 ; 2306-1278

    Περιγραφή αρχείου: application/pdf

    Relation: https://www.nii-kpssz.com/jour/article/view/1581/1078; https://www.nii-kpssz.com/jour/article/downloadSuppFile/1581/1864; Барбараш О.Л., Карпов Ю.А., Панов А.В., и др. Стабильная ишемическая болезнь сердца. Клинические рекомендации 2024. Российский кардиологический журнал. 2024;29(9):6110. doi:10.15829/1560-4071-2024-6110.; Российское кардиологическое общество (РКО). Острый инфаркт миокарда с подъемом сегмента ST электрокардиограммы. Клинические рекомендации 2020 // Российский кардиологический журнал. 2020 Т.25, №11. С.4103. doi:10.15829/29/1560-4071-2020-4103; Llerena-Velastegui J, Zumbana-Podaneva K, Velastegui-Zurita S, Mejia-Mora M, Perez-Tomassetti J, Cabrera-Cruz A, Haro-Arteaga P, de Jesus ACFS, Coelho PM, Sanahuja-Montiel C. Comparative Efficacy of Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in the Treatment of Ischemic Heart Disease: A Systematic Review and Meta-Analysis of Recent Randomized Controlled Trials. Cardiol Res. 2024 Jun;15(3):153-168. doi:10.14740/cr1638.; Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM, Bischoff JM, Bittl JA, Cohen MG, DiMaio JM, Don CW, Fremes SE, Gaudino MF, Goldberger ZD, Grant MC, Jaswal JB, Kurlansky PA, Mehran R, Metkus TS Jr, Nnacheta LC, Rao SV, Sellke FW, Sharma G, Yong CM, Zwischenberger BA. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022 Jan 18;145(3):e4-e17. doi:10.1161/CIR.0000000000001039.; Jobs A, Desch S, Freund A, Feistritzer HJ, Thiele H. Revascularization Strategy in Myocardial Infarction with Multivessel Disease. J Clin Med. 2024 Mar 26;13(7):1918. doi:10.3390/jcm13071918.; Timmis A, Aboyans V, Vardas P, Townsend N, Torbica A, Kavousi M, Boriani G, Huculeci R, Kazakiewicz D, Scherr D, Karagiannidis E, Cvijic M, Kapłon-Cieślicka A, Ignatiuk B, Raatikainen P, De Smedt D, Wood A, Dudek D, Van Belle E, Weidinger F; ESC National Cardiac Societies. European Society of Cardiology: the 2023 Atlas of Cardiovascular Disease Statistics. Eur Heart J. 2024 Oct 7;45(38):4019-4062. doi:10.1093/eurheartj/ehae466.; https://data-explorer.oecd.org/; Shawon MSR, Falster MO, Hsu B, Yu J, Ooi SY, Jorm L. Trends and Outcomes for Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in New South Wales from 2008 to 2019. Am J Cardiol. 2023 Jan 15;187:110-118. doi:10.1016/j.amjcard.2022.10.047; Alkhouli M, Alqahtani F, Kalra A, Gafoor S, Alhajji M, Alreshidan M, Holmes DR, Lerman A. Trends in Characteristics and Outcomes of Patients Undergoing Coronary Revascularization in the United States, 2003-2016. JAMA Netw Open. 2020 Feb 5;3(2):e1921326. doi:10.1001/jamanetworkopen.2019.21326.; Семенов В.Ю., Коваленко О.А. Динамика операций коронарного шунтирования в некоторых федеральных округах Российской Федерации в 2019–2021 годах. Комплексные проблемы сердечно-сосудистых заболеваний. 2024;13(3): 83-91. DOI:10.17802/2306-1278-2024-13-3-83-91; Алекян Б.Г., Бойцов С.А., Маношкина Е.М., Ганюков В.И. Реваскуляризация миокарда в Российской Федерации при остром коронарном синдроме в 2016-2020 гг. Кардиология. 2021;61(12):4-15. https://doi.org/10.18087/cardio.2021.12.n1879; Алекян Б.Г., Бойцов С.А., Ганюков В.И., Маношкина Е.М. Влияние пандемии COVID-19 на реваскуляризацию миокарда у пациентов с острым коронарным синдромом в Российской Федерации. Рациональная Фармакотерапия в Кардиологии. 2022;18(4):411-419. https://doi.org/10.20996/1819-6446-2022-08-03; Klein LW, Abugroun A, Daoud H. Rates of revascularization and PCI:CABG ratio: a new indicator predicting in-hospital mortality in acute coronary syndromes. Coron Artery Dis. 2022 Mar 1;33(2):69-74. doi:10.1097/MCA.0000000000001073; Chua TKT, Gao F, Chia SY, Sin KYK, Naik MJ, Tan TE, Tham YC. Long-term mortality after isolated coronary artery bypass grafting and risk factors for mortality. J Cardiothorac Surg. 2024 Jul 10;19(1):429. doi:10.1186/s13019-024-02943-0.; Hokkanen, M., Huhtala, H., Laurikka, J. et al. The effect of postoperative complications on health-related quality of life and survival 12 years after coronary artery bypass grafting – a prospective cohort study. J Cardiothorac Surg 16, 173 (2021). https://doi.org/10.1186/s13019-021-01527-6; Almramhi, K., Aljehani, M., Bamuflih, M., Alghamdi, S. ., Banser, S. ., Almousa, A. ., ALABDULWAHAB, S. ., & Al-Ebrahim, K. . (2022). Frequency and Risk Factors of Unplanned 30-Day Readmission After Open Heart Surgeries: A Retrospective Study in a Tertiary Care Center. The Heart Surgery Forum, 25(4), E608-E615. https://doi.org/10.1532/hsf.4875; Silverborn, M., Heitmann, L.A., Sveinsdottir, N. et al. Non-infectious sternal dehiscence after coronary artery bypass surgery. J Cardiothorac Surg 17, 249 (2022). https://doi.org/10.1186/s13019-022-02015-1; Madhavan MV, Kirtane AJ, Redfors B, Généreux P, Ben-Yehuda O, Palmerini T, Benedetto U, Biondi-Zoccai G, Smits PC, von Birgelen C, Mehran R, McAndrew T, Serruys PW, Leon MB, Pocock SJ, Stone GW. Stent-Related Adverse Events >1 Year After Percutaneous Coronary Intervention. J Am Coll Cardiol. 2020 Feb 18;75(6):590-604. doi:10.1016/j.jacc.2019.11.058; Krittanawong, C., Khawaja, M., Virk, H.U.H. et al. Strategies for chronic coronary disease: A brief guide for clinicians. npj Cardiovasc Health 1, 6 (2024). https://doi.org/10.1038/s44325-024-00006-w; Иванов С.В., Сумин А.Н. Современные тенденции рутинной реваскуляризации миокарда. Комплексные проблемы сердечно-сосудистых заболеваний. 2021;10(2):25-35. https://doi.org/10.17802/2306-1278-2021-10-2-25-35

  4. 4
    Academic Journal

    Πηγή: Medical Herald of the South of Russia; Том 15, № 1 (2024); 148-158 ; Медицинский вестник Юга России; Том 15, № 1 (2024); 148-158 ; 2618-7876 ; 2219-8075 ; 10.21886/2219-8075-2024-15-1

    Περιγραφή αρχείου: application/pdf

    Relation: https://www.medicalherald.ru/jour/article/view/1874/1018; https://www.medicalherald.ru/jour/article/downloadSuppFile/1874/871; https://www.medicalherald.ru/jour/article/downloadSuppFile/1874/872; https://www.medicalherald.ru/jour/article/downloadSuppFile/1874/873; https://www.medicalherald.ru/jour/article/downloadSuppFile/1874/874; https://www.medicalherald.ru/jour/article/downloadSuppFile/1874/875; https://www.medicalherald.ru/jour/article/downloadSuppFile/1874/876; https://www.medicalherald.ru/jour/article/downloadSuppFile/1874/877; https://www.medicalherald.ru/jour/article/downloadSuppFile/1874/878; https://www.medicalherald.ru/jour/article/downloadSuppFile/1874/894; https://www.medicalherald.ru/jour/article/downloadSuppFile/1874/895; https://www.medicalherald.ru/jour/article/downloadSuppFile/1874/896; https://www.medicalherald.ru/jour/article/downloadSuppFile/1874/897; https://www.medicalherald.ru/jour/article/downloadSuppFile/1874/898; Li D, Gao S. The interplay between T lymphocytes and macrophages in myocardial ischemia/reperfusion injury. Mol Cell Biochem. 2023. Epub ahead of print. PMID: 37540399. https://doi.org/10.1007/s11010-023-04822-z.; Добрынина М.А., Зурочка А.В., Комелькова М.В., Ло Ш., Зурочка В.А. и др. Исследование экспрессии CD45+ и CD46+ на субпопуляциях лимфоцитов периферической крови постковидных пациентов. Российский иммунологический журнал. 2022;25(4):431-436.; Добрынина М.А., Ибрагимов Р.В., Крицкий И.С., Верховская М.Д., Мосунов А.А., и др. Постковидный синдром иммунопатологии. Характеристика фенотипических изменений иммунной системы у постковидных пациентов. Медицинская иммунология. 2023;25(4):791-796.; Del Prete A, Conway F, Della Rocca DG, Biondi-Zoccai G, De Felice F, et al. COVID-19, Acute Myocardial Injury, and Infarction. Card Electrophysiol Clin. 2022;14(1):29-39. https://doi.org/10.1016/j.ccep.2021.10.004; Tajbakhsh A, Gheibi Hayat SM, Taghizadeh H, Akbari A, et al. COVID-19 and cardiac injury: clinical manifestations, biomarkers, mechanisms, diagnosis, treatment, and follow up. Expert Rev Anti Infect Ther. 2021;19(3):345-357. https://doi.org/10.1080/14787210.2020.1822737.; Raman B, Bluemke DA, Lüscher TF, Neubauer S. Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus. Eur Heart J. 2022;43(11):1157-1172. https://doi.org/10.1093/eurheartj/ehac031; Zuin M, Rigatelli G, Battisti V, Costola G, Roncon L, Bilato C. Increased risk of acute myocardial infarction after COVID-19 recovery: A systematic review and meta-analysis. Int J Cardiol. 2023;372:138-143. https://doi.org/10.1016/j.ijcard.2022.12.032; Azevedo RB, Botelho BG, Hollanda JVG, Ferreira LVL, Junqueira de Andrade LZ, et al. Covid-19 and the cardiovascular system: a comprehensive review. J Hum Hypertens. 2021;35(1):4-11. https://doi.org/10.1038/s41371-020-0387-4; Савчук К.С. Особенности Т-клеточного звена иммунитета и уровень натуральных киллеров у больных, перенесших COVID-19 с нарушениями углеводного обмена. Медицинская иммунология. 2023;25(4):797-802.; Савчук К.С., Рябова Л.В. Состояние функциональной активности нейтрофилов у больных с различными вариантами нарушений углеводного обмена, перенесших SARSCoV-2. Вестник Уральской медицинской академической науки. 2022;3:315-321.; Zhang L, Wang Z, Wang D, Zhu J, Wang Y. CD8+CD28+ T cells might mediate injury of cardiomyocytes in acute myocardial infarction. Mol Immunol. 2018;101:74-79. https://doi.org/10.1016/j.molimm.2018.05.015; Зурочка А.В., Хайдуков С.В., Кудрявцев И.В., Черешнев В.А. Проточная цитометрия в биомедицинских исследованиях. Екатеринбург: РИО УрО РАН; 2018.; Хайдуков С.В., Байдун Л.А., Зурочка А.В., Тотолян А.А. Стандартизованная технология «Исследование субпопуляционного состава лимфоцитов периферической крови с применением проточных цитофлюориметров-анализаторов» (проект). Медицинская иммунология. 2012;14(3):255-268.; Маянский А.Н., Пазюк Е.А., Макарова Т. П., Паршакова Р.А., Пикуза О.И. Механизм и диагностические возможности реакции восстановления нитросинего тетразолия нейтрофилами человека. Казанский медицинский журнал. 1981;62(4):64-68.; Маянский, А.Н., Пикуза О.И. Клинические аспекты фагоцитоза. Казань: Магариф; 1993.; Фрейдлин И. С. Методы изучения фагоцитирующих клеток при оценке иммунного статуса человека: Учеб. пособие. Л.; 1986.; Маркина Н. В., Степнова О. А., Шамаева Т. Н. Учебное пособие по статистической обработке медико-биологических данных. Челябинск; 2014.; Casarotti ACA, Teixeira D, Longo-Maugeri IM, Ishimura ME, Coste MER, et al. Role of B lymphocytes in the infarcted mass in patients with acute myocardial infarction. Biosci Rep. 2021;41(2):BSR20203413. https://doi.org/10.1042/BSR20203413; Santos-Zas I, Lemarié J, Zlatanova I, Cachanado M, Seghezzi JC, et al. Cytotoxic CD8+ T cells promote granzyme B-dependent adverse post-ischemic cardiac remodeling. Nat Commun. 2021;12(1):1483. https://doi.org/10.1038/s41467-021-21737-9; https://www.medicalherald.ru/jour/article/view/1874

  5. 5
  6. 6
    Academic Journal
  7. 7
  8. 8
    Academic Journal

    Πηγή: Russian Journal of Transplantology and Artificial Organs; Том 26, № 1 (2024); 26-35 ; Вестник трансплантологии и искусственных органов; Том 26, № 1 (2024); 26-35 ; 1995-1191

    Περιγραφή αρχείου: application/pdf

    Relation: https://journal.transpl.ru/vtio/article/view/1652/1560; https://journal.transpl.ru/vtio/article/view/1652/1624; Thompson S, James M, Wiebe N, Hemmelgarn B, Manns B, Klarenbach S et al. Cause of Death in Patients with Reduced Kidney Function. J Am Soc Nephrol. 2015; 26 (10): 2504–2511. doi:10.1681/ASN.2014070714.; Sarnak MJ, Amann K, Bangalore S, Cavalcante JL, Charytan DM, Craig JC et al. Chronic Kidney Disease and Coronary Artery Disease: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019; 74 (14): 1823–1838. doi:10.1016/j.jacc.2019.08.1017.; ERA Registry Annual Report 2021 %7C EKPF. Accessed September 11, 2023. https://ekpf.eu/era-registry-annualreport-2021/.; Hariharan S, Israni AK, Danovitch G. Long-Term Survival after Kidney Transplantation. N Engl J Med. 2021; 385 (8): 729–743. doi:10.1056/NEJMra2014530.; Мартынов СА, Северина АС, Ларина ИИ, Шамхалова МШ, Арзуманов СВ, Пинчук АВ, Шестакова МВ. Подготовка пациента с сахарным диабетом 1-го типа на заместительной почечной терапии диализом к трансплантации почки. Проблемы эндокринологии. 2020; 66 (6): 18–30. https://doi.org/10.14341/probl12686.; Ewing EC, Edwards AR. Cardiovascular Disease Assessment Prior to Kidney Transplantation. Methodist Debakey Cardiovasc J. 2022; 18 (4): 50–61. doi:10.14797/mdcvj.1117.; Chadban SJ, Ahn C, Axelrod DA, Foster BJ, Kasiske BL, Kher V et al. KDIGO Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation. Transplantation. 2020; 104 (4S1 Suppl 1): S11–S103. doi:10.1097/TP.0000000000003136.; Karthikeyan V, Ananthasubramaniam K. Coronary Risk Assessment and Management Options in Chronic Kidney Disease Patients Prior to Kidney Transplantation. Current Cardiology Reviews. 2009; 5 (3): 177. doi:10.2174/157340309788970342.; Hakeem A, Bhatti S, Chang SM. Screening and risk stratification of coronary artery disease in end-stage renal disease. JACC Cardiovasc Imaging. 2014; 7 (7): 715–728. doi:10.1016/j.jcmg.2013.12.015.; Nimmo A, Forsyth JL, Oniscu GC, Robb M, Watson C, Fotheringham J et al. A propensity score-matched analysis indicates screening for asymptomatic coronary artery disease does not predict cardiac events in kidney transplant recipients. Kidney Int. 2021; 99 (2): 431–442. doi:10.1016/j.kint.2020.10.019.; Genovesi S, Boriani G, Covic A, Vernooij RWM, Combe C, Burlacu A et al. Sudden cardiac death in dialysis patients: different causes and management strategies. Nephrol Dial Transplant. 2021; 36 (3): 396–405. doi:10.1093/ndt/gfz182.; Vadalà G, Alaimo C, Buccheri G, Di Fazio L, Di Caccamo L, Sucato V et al. Screening and Management of Coronary Artery Disease in Kidney Transplant Candidates. Diagnostics (Basel). 2023; 13 (16): 2709. doi:10.3390/diagnostics13162709.; European Renal Best Practice Transplantation Guideline Development Group. ERBP Guideline on the Management and Evaluation of the Kidney Donor and Recipient. Nephrol Dial Transplant. 2013; 28 Suppl 2: ii1–71. doi:10.1093/ndt/gft218.; Lentine KL, Costa SP, Weir MR, Robb JF, Fleisher LA, Kasiske BL et al. Cardiac disease evaluation and management among kidney and liver transplantation candidates: a scientific statement from the American Heart Association and the American College of Cardiology Foundation: endorsed by the American Society of Transplant Surgeons, American Society of Transplantation, and National Kidney Foundation. Circulation. 2012; 126 (5): 617–663. doi:10.1161/CIR.0b013e31823eb07a.; Cheng XS, VanWagner LB, Costa SP, Axelrod DA, Bangalore S, Norman SP et al. Emerging Evidence on Coronary Heart Disease Screening in Kidney and Liver Transplantation Candidates: A Scientific Statement From the American Heart Association: Endorsed by the American Society of Transplantation. Circulation. 2022; 146 (21): e299–e324. doi:10.1161/CIR.0000000000001104.; Halvorsen S, Mehilli J, Cassese S, Hall TS, Abdelhamid M, Barbato E et al. 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. Eur Heart J. 2022; 43 (39): 3826–3924. doi:10.1093/eurheartj/ehac270.; Jegatheesan D, Yang W, Krishnasamy R, Hawley CM, Johnson DW. Cardiovascular Disease in Dialysis Patients. Aspects in Dialysis. Published online 2017.; Siddiqui MU, Junarta J, Marhefka GD. Coronary Revascularization Versus Optimal Medical Therapy in Renal Transplant Candidates With Coronary Artery Disease: A Systematic Review and Meta-Analysis. J Am Heart Assoc. 2022; 11 (4): e023548. doi:10.1161/JAHA.121.023548.; Kamran H, Kupferstein E, Sharma N, Singh G, Sowers JR, Whaley-Connell A et al. Revascularization versus Medical Management of Coronary Artery Disease in Prerenal Transplant Patients: A Meta-Analysis. Cardiorenal Med. 2018; 8 (3): 192–198. doi:10.1159/000487763.; Liao GZ, Li YM, Bai L, Ye YY, Peng Y. Revascularization vs. Conservative Medical Treatment in Patients With Chronic Kidney Disease and Coronary Artery Disease: A Meta-Analysis. Front Cardiovasc Med. 2021; 8: 818958. doi:10.3389/fcvm.2021.818958.; Zheng L, Wang X, Zhong YC. Comparison of revascularization with conservative medical treatment in maintenance dialysis patient with coronary artery disease: a systemic review and meta-analysis. Front Cardiovasc Med. 2023; 10: 1143895. doi:10.3389/fcvm.2023.1143895.; Yong J, Tian J, Zhao X, Yang X, Xing H, He Y, Song X. Optimal treatment strategies for coronary artery disease in patients with advanced kidney disease: a meta-analysis. Ther Adv Chronic Dis. 2021; 12: 20406223211024367. doi:10.1177/20406223211024367.; Wang Z, Gong Y, Fan F, Yang F, Qiu L, Hong T, Huo Y. Coronary artery bypass grafting vs. drug-eluting stent implantation in patients with end-stage renal disease requiring dialysis. Ren Fail. 2020; 42 (1): 107–112. doi:10.1080/0886022X.2019.1710187.; Taliercio JJ, Nakhoul G, Mehdi A, Yang W, Sha D, Schold JD et al. Aspirin for Primary and Secondary Prevention of Mortality, Cardiovascular Disease, and Kidney Failure in the Chronic Renal Insufficiency Cohort (CRIC) Study. Kidney Med. 2022; 4 (11): 100547. doi:10.1016/j.xkme.2022.100547.; Chen ZW, Wu CK, Yang YH, Huang JW, Wu VC, Lee JK et al. Efficacy of Antiplatelet Agent Usage for Primary and Secondary Prevention in Dialysis Patients: a Nationwide Data Survey and Propensity Analysis. Cardiovasc Drugs Ther. 2019; 33 (4): 471–479. doi:10.1007/s10557-019-06882-0.; Summaria F, Giannico MB, Talarico GP, Patrizi R. Antiplatelet Therapy in Hemodialysis Patients Undergoing Percutaneous Coronary Interventions. Nephrourol Mon. 2015; 7 (4): e28099. doi:10.5812/numonthly.28099.; Park S, Choi YJ, Kang JE, Kim MG, Jung Geum M, Kim SD, Rhie SJ. P2Y12 Antiplatelet Choice for Patients with Chronic Kidney Disease and Acute Coronary Syndrome: A Systematic Review and Meta-Analysis. J Pers Med. 2021; 11 (3): 222. doi:10.3390/jpm11030222.; Becker RC, Helmy T. Are at least 12 months of dual antiplatelet therapy needed for all patients with drug-eluting stents? Not all patients with drug-eluting stents need at least 12 months of dual antiplatelet therapy. Circulation. 2015; 131 (22): 2010–2019; discussion 2019. doi:10.1161/CIRCULATIONAHA.114.013281.; Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. European Heart Journal. 2020; 41 (3): 407–477. doi:10.1093/eurheartj/ehz425.; Mavrakanas TA, Chatzizisis YS, Gariani K, Kereiakes DJ, Gargiulo G, Helft G et al. Duration of Dual Antiplatelet Therapy in Patients with CKD and Drug-Eluting Stents: A Meta-Analysis. Clin J Am Soc Nephrol. 2019; 14 (6): 810–822. doi:10.2215/CJN.12901018.; Chen YT, Chen HT, Hsu CY, Chao PW, Kuo SC, Ou SM, Shih CJ. Dual Antiplatelet Therapy and Clinical Outcomes after Coronary Drug-Eluting Stent Implantation in Patients on Hemodialysis. Clin J Am Soc Nephrol. 2017; 12 (2): 262–271. doi:10.2215/CJN.04430416.; Park S, Kim Y, Jo HA, Lee S, Kim MS, Yang BR et al. Clinical outcomes of prolonged dual antiplatelet therapy after coronary drug-eluting stent implantation in dialysis patients. Clin Kidney J. 2020; 13 (5): 803–812. doi:10.1093/ckj/sfaa037.; Giustino G,ChieffoA, Palmerini T, Valgimigli M, Feres F, Abizaid A et al. Efficacy and Safety of Dual Antiplatelet Therapy After Complex PCI. J Am Coll Cardiol. 2016; 68 (17): 1851–1864. doi:10.1016/j.jacc.2016.07.760.; Carrero JJ, Varenhorst C, Jensevik K, Szummer K, Lagerqvist B, Evans M et al. Long-term versus short-term dual antiplatelet therapy was similarly associated with a lower risk of death, stroke, or infarction in patients with acute coronary syndrome regardless of underlying kidney disease. Kidney Int. 2017; 91 (1): 216–226. doi:10.1016/j.kint.2016.09.014.; Palmer SC, Craig JC, Navaneethan SD, Tonelli M, Pellegrini F, Strippoli GFM. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2012; 157 (4): 263–275. doi:10.7326/0003-4819-157-4201208210-00007.; Драпкина ОМ, Корнеева ОН. Статины при хронической болезни почек. Существует ли препарат выбора? Кардиоваскулярная терапия и профилактика. 2015; 14 (6): 76–80.; Wanner C, Tonelli M. Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int. 2014; 85 (6): 1303–1309. doi:10.1038/ki.2014.31.; K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. American journal of kidney diseases: the official journal of the National Kidney Foundation. 2005; 45 (4 Suppl 3). doi:10.1053/j.ajkd.2005.01.019.; Authors/Task Force Members, ESC Committee for Practice Guidelines (CPG), ESC National Cardiac Societies. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019; 290: 140–205. doi:10.1016/j.atherosclerosis.2019.08.014.; Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019; 139 (25): e1082–e1143. doi:10.1161/CIR.0000000000000625.; Подкаменный ВА, Желтовский ЮВ, Шаравин АА, Козина ОА, Вырупаев АВ. Минимально инвазивное коронарное шунтирование у больного после трансплантации почки. Нефрология и диализ. 2019; 21 (3): 378–381. doi:10.28996/2618-9801-2019-3-378-381.; Kahn MR, Fallahi A, Kim MC, Esquitin R, Robbins MJ. Coronary artery disease in a large renal transplant population: implications for management. Am J Transplant. 2011; 11 (12): 2665–2674. doi:10.1111/j.16006143.2011.03734.x.; El-Qushayri AE, Reda A. Surgical versus interventional coronary revascularization in kidney transplant recipients: a systematic review and meta-analysis. Int Urol Nephrol. Published online March 12, 2023. doi:10.1007/s11255-023-03546-9.; Lang J, Buettner S, Weiler H, Papadopoulos N, Geiger H, Hauser I et al. Comparison of interventional and surgical myocardial revascularization in kidney transplant recipients – A single-centre retrospective analysis. IJC Heart & Vasculature. 2018; 21: 96–102. doi:10.1016/j.ijcha.2018.10.010.; Рядовой ИГ, Миронков АБ, Миронков БЛ, Бабаян ГР, Гонтуар МГ, Честухин ВВ. Проблемы эндоваскулярной реваскуляризации миокарда у реципиентов почечного трансплантата. Международный журнал интервенционной кардиоангиологии. 2011; (27–28): 35–39.; Kasiske BL, Zeier MG, Chapman JR, Craig JC, Ekberg H, Garvey CA et al. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney Int. 2010; 77 (4): 299–311. doi:10.1038/ki.2009.377.; Holdaas H, Fellström B, Jardine AG, Holme I, Nyberg G, Fauchald P et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet. 2003; 361 (9374): 2024–2031. doi:10.1016/S01406736(03)13638-0.; Holdaas H, Fellström B, Jardine AG, Nyberg G, Grönhagen-Riska C, Madsen S et al. Beneficial effect of early initiation of lipid-lowering therapy following renal transplantation. Nephrol Dial Transplant. 2005; 20 (5): 974–980. doi:10.1093/ndt/gfh735.; Chmielnicka K, Heleniak Z, Dębska-Ślizień A. Dyslipidemia in Renal Transplant Recipients. Transplantology. 2022; 3 (2): 188–199. doi:10.3390/transplantology3020020.; Akman B, Uyar M, Afsar B, Sezer S, Ozdemir FN, Haberal M. Lipid profile during azathioprine or mycophenolate mofetil combinations with cyclosporine and steroids. Transplant Proc. 2007; 39 (1): 135–137. doi:10.1016/j.transproceed.2006.10.210.; Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011; 377 (9784): 2181–2192. doi:10.1016/S01406736(11)60739-3.; Dad T, Tighiouart H, Joseph A, Bostom A, Carpenter M, Hunsicker L et al. Aspirin Use and Incident Cardiovascular Disease, Kidney Failure, and Death in Stable Kidney Transplant Recipients: A Post Hoc Analysis of the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial. Am J Kidney Dis. 2016; 68 (2): 277–286. doi:10.1053/j.ajkd.2016.01.019.; https://journal.transpl.ru/vtio/article/view/1652

  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
    Academic Journal
  18. 18
    Academic Journal

    Συγγραφείς: Terenda, N. O., Petrashyk, Yu. M.

    Πηγή: Hospital Surgery. Journal named by L.Ya. Kovalchuk; No. 1 (2017); 91-95 ; Госпитальная хирургия. Журнал имени Л.А. Ковальчука; № 1 (2017); 91-95 ; Шпитальна хірургія. Журнал імені Л. Я. Ковальчука; № 1 (2017); 91-95 ; 2414-4533 ; 1681-2778 ; 10.11603/2414-4533.2017.1

    Περιγραφή αρχείου: application/pdf

  19. 19
    Academic Journal

    Περιγραφή αρχείου: application/pdf

    Relation: Клінічні характеристики пацієнтів в умовах рутинної седації при ендоваскулярному лікуванні ІХС / Д. О. Дзюба, М. В. Болюк, О. О. Сиворакша, О. А. Лоскутов // Актуальні проблеми сучасної медицини: Вісник Української медичної стоматологічної академії. – 2020. – Т. 20, вип. 3 (71). – С. 95–102.; https://repository.pdmu.edu.ua/handle/123456789/15562

  20. 20
    Academic Journal

    Συγγραφείς: I. S. Yavelov, И. С. Явелов

    Πηγή: Aterotromboz = Atherothrombosis; № 2 (2020); 66-74 ; Атеротромбоз; № 2 (2020); 66-74 ; 2658-5952 ; 2307-1109 ; 10.21518/2307-1109-2020-2

    Περιγραφή αρχείου: application/pdf

    Relation: https://www.aterotromboz.ru/jour/article/view/228/253; Ibanez B., James S., Agewall S., Antunes M.J., Bucciarelli-Ducci C., Bueno H., Caforio A.L.P. et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119-177. doi:10.1093/eurheartj/ehx393.; Roffi M., Patrono C., Collet J.P., Mueller C., Valgimigli M., Andreotti F. et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(3):267 -315. doi:10.1093/eurheartj/ehv320.; Collet J.P., Thiele H., Barbato E., Barthelemy O., Bauersachs J., Bhatt D.L. et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2020;ehaa575. doi:10.1093/eurheartj/ehaa575.; Thiele H., Akin I., Sandri M., Fuernau G., de Waha S., Meyer-Saraei R. et al. PCI strategies in patients with acute myocardial infarction and cardiogenic shock. N Engl J Med. 2017;377(25):2419-2432. doi:10.1056/NEJMoa1710261.; Thiele H., Akin I., Sandri M., de Waha-Thiele S., Meyer-Saraei R., Fuernau G. et al. One-year outcomes after PCI strategies in cardiogenic shock. N Engl J Med. 2018;379(18):1699-1710. doi:10.1056/NEJMoa1808788.; Montalescot G., Bolognese L., Dudek D., Goldstein P., Hamm C., Tanguay J.F. et al. Pretreatment with pra-sugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med. 2013;369(11):999-1010. doi:10.1056/NEJMoa1308075.; Wallentin L., Becker R.C., Budaj A., Cannon C.P., Emanuelsson H., Held C. et al. Ticagrelor versus clopi-dogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045-1057. doi:10.1056/NEJMoa0904327.; Wiviott S.D., Braunwald E., McCabe C.H., Montalescot G., Ruzyllo W., Gottlieb S. et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001-2015. doi:10.1056/NEJMoa0706482.; Motovska Z., Hlinomaz O., Miklik R., Hromadka M., Varvarovsky I., Dusek J. et al. Prasugrel versus ticagrelor in patients with acute myocardial infarction treated with primary percutaneous coronary intervention: multicenter randomized PRAGUE-18 Study. Circulation. 2016;134(21):1603-1612. doi:10.1161/CIRCULATIONAHA.116.024823.; Motovska Z., Hlinomaz O., Kala P., Hromadka M., Knot J., Varvarovsky I. et al. 1-Year Outcomes of Patients Undergoing Primary Angioplasty for Myocardial Infarction Treated With Prasugrel Versus Ticagrelor. J Am Coll Cardiol. 2018;71(4):371-381. doi:10.1016/j.jacc.2017.11.008.; SchQpke S., Neumann F.J., Menichelli M., Mayer K., Bernlochner I., Wohrle J. et al. Ticagrelor or pra-sugrel in patients with acute coronary syndromes. N Engl J Med. 2019;381(16):1524-1534. doi:10.1056/NEJMoa1908973.; Ndrepepa G., Kastrati A., Menichelli M., Neumann F.J., Wohrle J., Bernlochner I. et al. Ticagrelor or Prasugrel in Patients With Acute Coronary Syndromes and Diabetes Mellitus. JACC Cardiovasc Interv. 2020;13(19):2238-2247. doi:10.1016/j.jcin.2020.07.032.; Menichelli M., Neumann F.J., Ndrepepa G., Mayer K., Wohrle J., Bernlochner I. et al. Age- and Weight-Adapted Dose of Prasugrel Versus Standard Dose of Ticagrelor in Patients With Acute Coronary Syndromes: Results From a Randomized Trial. Ann Intern Med. 2020;173(6):436-444. doi:10.7326/M20-1806.; Sulzgruber P., Niessner A. Prasugrel vs. ticagrelor after acute coronary syndrome: a critical appraisal of the ISAR-REACT 5 trial. Eur Heart J Cardiovasc Pharmacother. 2020;6(5):273-274. doi:10.1093/ehjcvp/pvz077.; Jneid H. Ticagrelor or Prasugrel in Acute Coronary Syndromes - The Winner Takes It All? N Engl J Med. 2019;381(16):1582-1584. doi:10.1056/NEJMe1911207.; Banning A.P., Crea F., LQscher T.F. The year in cardiology: acute coronary syndromes. Eur Heart J. 2020;41(7):821-832. doi:10.1093/eurheartj/ehz942.; Kubica J., Jaguszewski M. ISAR-REACT 5 - What have we learned? Cardiol J. 2019;26(5):427-428. doi:10.5603/CJ.a2019.0090.; Bittl J.A., Yong C.M., Sharma G. When to Believe Unexpected Results for Ticagrelor or Prasugrel. Never Rarely Sometimes Always. JACC Cardiovasc Interv. 2020;13(19):2248-2250. doi:10.1016/j.jcin.2020.08.012.; https://www.aterotromboz.ru/jour/article/view/228